Understanding the phenomenon of persistence in mycobacterial infections

Indian Journal of Leprosy

Volumn 69, Issue 4, 1997, Pages 385-393

  Gupta, U D ^a   Katoch, V M ^a  

^a NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; GLYOXYLIC ACID; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

BACTERIAL METABOLISM; CLINICAL TRIAL; DRUG PENETRATION; ENVIRONMENTAL FACTOR; HUMAN; LEPROSY; MOLECULAR GENETICS; MYCOBACTERIOSIS; NONHUMAN; PERSISTENT INFECTION; RELAPSE; REVIEW; TUBERCULOSIS;

ANIMALS; DRUG RESISTANCE, MICROBIAL; HUMANS; LEPROSY; MICE; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; TUBERCULOSIS;

EID: 0031413601     PISSN: 02549395     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Arunthathi S, Chacko CJG 1988. Proceedings of Joint Indian and THELEP Scientists on MDT in leprosy. Karigiri, Schieffelin Leprosy Research & Training Centre.
2. Becx-Bleumink M 1992. Relapses in leprosy patients after release from dapsone monotherapy; Experience in leprosy control program in All Africa Leprosy and Rehabilitation Training Centre (ALERT), Ethiopia. Int J Lepr 60:161-172.
3. Bharadwaj VP, Katoch VM, Sharma VD et al 1987. Metabolic studies on mycobacteria IV. Assay of isocitrate lyase and malate synthase activity in M. leprae. Indian J Lepr 59: 158-162.
4. Bigger JW 1944. Treatment of staphylococcal infections with pencillin intermittent sterilization. Lancet 247:497-500.
5. Blanc L, Jamet P, Faye O et al 1993. Short-term rifampin regimen for leprosy yield to high risk of relapse. 14th Int Lepr Cong, Orlando, USA: Abst Ch 27. Int J Lepr 61 Suppl:7A.
6. Boerrigter G, Pönnighaus JM, Fine PEM 1988. Preliminary appraisal of WHO-recommended multidrug regimen in paucibacillary leprosy patients in Malawi. Int J Lepr 56:408-417.
7. Boerrigter G, Pönnighaus JM, Fine PEM. Rosamund J 1991. Four years follow-up results of a WHO recommended multiple drug regimen in paucibacillary leprosy patients in Malawi. Int J Lepr 59:255-261.
8. British Thoracic and Tuberculosis Association 1976. Short course chemotherapy in pulmonary tuberculosis. A controlled trial by British Thoracic and Tuberculosis Association. Lancet ii: 1102-1106.
9. Brouet G, Roussel G 1977. General Report. Trial 6.9.12. Overall methods and results. Rev Fr Mal Resp 5 Suppl 1:5-13.
10. East African/British Medical Research Council Study 1977. Results after 5 years of controlled comparison of a six month and a standard 18 month regimen of chemotherapy for pulmonary tuberculosis. Amer Rev Resp Dis 116:3-8.
11. Ekambaram V, Rao MK 1991. Relapse rate in paucibacillary leprosy. Indian J Lepr 63: 34-42.
12. Ganapati R 1989. Efficacy of chemotherapy in paucibacillary leprosy - Epidemiological issues and assessment problems. Lepr Res Rev - Proc Indo-UK Workshop Lepr Res, Agra, A CJIL publication, pp 116-120.
13. Georgiev GD, McDougall AC 1990. A re-appraisal of clinical and bacteriological criteria in the implementation of multiple drug therapy for leprosy control programmes and proposal for their better use. Lepr Rev 64:64-72.
14. Glazious P, Chansin R, Speigel A, Cartel JL 1990. The usefulness of systematic follow-up of tuberculosis for the diagnosis of relapse in French Polynesia between 1971 and 1984. Vern K Acad Geneeskd Belg 52:801-810.
15. Grau J, Marquillas E, Priu R, Tomer J 1990. Pulmonary tubeculosis and tolerance of a six month treatment schedule using 4 drugs. Rev Clin Esp 186:116-118.
16. Grugni A, Nadkarni NJ, Kini MS, Mehta VR 1990. Relapses in paucibacillary leprosy after MDT - a clinical study. Int J Lepr 58:19-24.
17. IAL 1984. Consensus on treatment regimens in leprosy and problems of drug delivery. Indian J Lepr 56:154-158.
18. Jamet P, Ji B. and the Marchoux Chemotherapy Study Group 1995. Relapse after long-term follow-up of multibacillary patients treated by WHO multidrug regimen. Int J Lepr 63:195-201.
19. Katoch K, Sreevatsa, Ramanathan U, Ramu G 1988. Pyrazinamide as a part of combined therapy for treatment of BL/LL patients. Int J Lepr 56:1-8.
20. Katoch K, Ramanathan U, Natarajan M et al 1989. Relapses in paucibacillary patients after treatment with short-term regimens containing rifampin. Int J Lepr 57:458-464.
21. Katoch K, Natarajan M, Bagga A, Katoch VM 1991. Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different durations of MDT. Int J Lepr 59:248-254.
22. Katoch K, Katoch VM, Natarajan M et al 1995. Treatment of highly bacilliferous BL/LL patients with combined chemotherapy and immunotherapy. Int J Lepr 63:202-212.
23. Katoch VM, Katoch K, Ramanathan U et al 1989. Effect of chemotherapy on viability of Mycobacterium leprae as determined by ATP content, morphological index and FDA-EB fluorescent staining. Int J Lepr 57:615-621.
24. Levy L 1976. Treatment failures in leprosy. Int J Lepr 44:177-182.
25. Madsen LH, Waite D, Ackerson L, Aorsburg CR Jr 1992. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifarnpicin. Q J Med 85:719-730.
26. Manjula Datta, Radhamani MP, Selvaraj R et al 1993. Critical assessment of smear positive pulmonary tuberculosis patients after chemotherapy under district tuberculosis programme. Tuber Lung Dis 74:180-186.
27. McDermott W 1957. Microbial persistence. Yale J Biol Med 30:257-291.
28. McDermott W, Tompsett R 1954. Activities of pyrazinamide and nicotinamide in acidic environment in vitro. Amer Rev Tub Pulm Dis 70:748-754.
29. Mitchison DA, Skelson JB 1956. The bactericidal activities of antituberculosis drugs. Amer Rev Tub Pulm Dis 74:101-112.
30. Murthy PS, Sirsi M, Ramakrishnan T 1973. Effect of age on enzymes of tricarboxylic acid and glyoxylate cycles of Mycobacterium tuberculosis H37Rv. Amer Rev Resp Dis 108:689-690.
31. NLEP 1994. National Leprosy Eradication Programme in India. Guidelines for multidrug treatment in non-endemic districts. New Delhi, Ministry of Health, Government of India.
32. Paramasivan CN, Chandrasekaran V, Santha T et al 1993. Bacteriological investigations for short-course chemotherapy under tuberculosis programme in two districts of India. Tuber Lung Dis 74:23-27.
33. Paramasivan CN 1994. New anti-mycobacterial drugs and their role in the treatment of tuberculosis patients. Indian J Tuber 41:7-16.
34. Pattyn SR, Dockx P. Rollin R, Saerens EJ 1976. Mycobacterium leprae: Persisters after treatment with dapsone and rifampin. Int J Lepr 44:154-158.
35. Pearson JMH, Rees RJW, Waters MFR 1975. Sulphone resistance in leprosy. Lancet ii:69-72.
36. Ramu G, Desikan KV 1979. A study of scrotal biopsy in subsided cases of lepromatous leprosy. Lepr India 51:341-347.
37. Rangaraj M, Rangaraj J 1986. Experience with multidrug therapy in Siera Leone: Clinical, operational and managerial analysis. Lepr Rev 57 Suppl:77-91.
38. Rani Balasubramanian, Sivasubramanian S, Vijayan VK et al 1990. Five year results of a 3 month and two 5 month regimens for the treatment of sputum positive pulmonary tuberculosis patients in South India. Tubercle 71:253-257.
39. Reddy PK, Mohiuddin SK 1988. Multidrug therapy in paucibacillary leprosy - a five year experience. Indian J Lepr 60:581-588.
40. Rees RJW, Waters MFR, Pearson JMH et al 1976. Long term treatment of resistant leprosy with rifampicin: clinical and bacteriological studies. Int J Lepr 44:170-176.
41. Salomao MA 1991. The National Tuberculosis Control Programme in Mozambique 1986-1990. Med Oncol Tumon Pharmacother 8:229-233.
42. Samuel NM, Samuel S, Adiga RB 1985. Treatment of paucibacillary leprosy patients with dapsone and rifampicin. Jap J Lepr 54:193-197.
43. Scharkoff H, Pohl S 1990. Tuberculosis relapses in East Inamide. S Afri Med J 77:390-391.
44. Shetty VP, Suchitra K, Uplekar MW, Antia NH 1992. Persisters of Mycobacterium leprae in the peripheral nerve as compared to skin of multidrug treated leprosy patients. Lepr Rev 63: 329-333.
45. Shennan DH 1993. The Ciskei Tuberculosis Information System. Cent Afri J Med 39:159-165.
46. Srrevatsa, Girdhar BK, Desikan KV 1988. Screening of drug resistant strains of M. leprae in lepromatous leprosy patients under multi-drug treatment. Indian J Med Res 87:139-143.
47. THELEP 1987. The THELEP controlled clinical trials. Int J Lepr 55 Suppl:864-868.
48. Toman K 1981. Bacterial persistence in leprosy. Int J Lepr 49:205-216.
49. Tuberculosis Association of India 1989. Recommended regimens. Cited in: Text book of Preventive and Social Medicine. Edn 12, eds JE Park, K Park. Jabalpur, Banarsi Das Bhanot publishers, pp 131-140.
50. Tuberculosis Research Centre, Madras and National Tuberculosis Institute, Bangalore 1986. A controlled clinical trial of 3 month and 5 month regimens in the treatment of sputum positive pulmonary tuberculosis in South India. Amer Rev Res Dis 134:27-32.
51. van Brakel W, Kist P, Noble S, O'Tovle S 1989. Relapses after multidrug therapy for leprosy; a preliminary study of 22 cases in West Nepal. Lepr Rev 60:45-50.
52. Waters MFR, Rees RJW, McDougall AC, Weddel AGM 1974. Ten years of dapsone in lepromatous leprosy: clinical, bacteriological and histological assessment and findings of viable leprosy bacilli. Lepr Rev 45:288-298.
53. Waters MFR, Ridley DS, Ridley MJ 1986. Clinical problems in initiation and assessment of multidrug therapy. Lepr Rev 57 Suppl:92-100.
54. Wayne LG, Lin KY 1982. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 37:1042-1049.
55. Wayne LG, Sramek HA 1979. Antigenic differences between extracts of actively replicating and synchronized resting cells of Mycobacterium tuberculosis. Infect Immun 24:363-370.
56. Witter RG 1952. The L-forms of H. pertussis in the mouse. J Gen Microbiol 6:311-317.
57. WHO 1982. Chemotherapy of leprosy for Control Programmes. Tech Rep Ser 675, Geneva, World Health Organization.
58. WHO 1988. WHO Expert Committee on leprosy - sixth report. Tech Rep Ser 768, Geneva, World Health Organization.